Bunce, Chris - University of Birmingham

个人简介

Professor Chris Bunce is a double alumnus of Birmingham and has pursued his research career here too. His PhD studies were undertaken in the Dept of Immunology. In 1997 he was awarded one of two inaugural Leukaemia Research Fund Bennett Senior Fellowships which he took in the Department of Medicine. In 2002 he moved to the School of Biosciences as a Leukaemia Research Fund Senior lecturer. In 2008 he became Reader in Experimental Haematological Oncology. Professor Bunce’s group received Programme support from the Leukaemia Research Fund in 2005 which was successfully renewed in 2010. This programme is shared with Professor Bunce’s long-term clinical collaborator Professor Mark Drayson.

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Nm23-H1 indirectly promotes the survival of acute myeloid leukaemia blast cells by binding to more mature components of the leukemic clone. Lilly AJ, Khanim FL, Hayden RE, Luong QT, Drayson MT, Bunce CM. Cancer Res. 2010 Dec 17. [Epub ahead of print] PMID: 21169412 Hypoxia triggers major metabolic changes in AML cells without altering indomethacin-induced TCA cycle deregulation. Lodi A, Tiziani S, Khanim FL, Drayson MT, Günther UL, Bunce CM, Viant MR. ACS Chem Biol. 2010 Oct 1. [Epub ahead of print] PMID: 20886892 Lycorine sensitizes CD40L protected chronic lymphocytic leukemia cells to bezafibrate and medroxyprogesterone acetate induced apoptosis but dasatanib does not overcome reported CD40-mediated drug resistance. Hayden RE, Pratt G, Drayson MT, Bunce CM. Haematologica. 2010 95(11):1889-96.PMID: 20634492 Extracellular Nm23H1 stimulates neurite outgrowth from dorsal root ganglia neurons in vitro independently of nerve growth factor supplementation or its nucleoside diphosphate kinase activity. Wright KT, Seabright R, Logan A, Lilly AJ, Khanim F, Bunce CM, Johnson WE. Biochem Biophys Res Commun. 2010; 398(1):79-85. PMID: 20558132 Elevated NCOR1 disrupts PPAR{alpha}/{gamma} signalling in prostate cancer and forms a targetable epigenetic lesion. Battaglia S, Maguire O, Thorne JL, Hornung LB, Doig CL, Liu S, Sucheston LE, Bianchi A, Khanim F, Gommersall LM, Coulter HS, Rakha S, Giddings I, O'Neill LP, Cooper CS, McCabe CJ, Bunce CM, Campbell MJ. Carcinogenesis. 2010; 31(9):1650-60. PMID: 20466759 Prostaglandin D(2) inhibits C2C12 myogenesis. Veli?a P, Khanim FL, Bunce CM. Mol Cell Endocrinol. 2010 May 5;319(1-2):71-8. PMID: 20109525 Combined bezafibrate and medroxyprogesterone acetate have efficacy without haematological toxicity in elderly and relapsed acute myeloid leukaemia (AML). Murray JA, Khanim FL, Hayden RE, Craddock CF, Holyoake TL, Jackson N, Lumley M, Bunce CM, Drayson MT. Br J Haematol. 2010 Apr;149(1):65-9. PMID: 20067564 Visfatin induces oxidative stress in differentiated C2C12 myotubes in an Akt- and MAPK-independent, NFkB-dependent manner. Oita RC, Ferdinando D, Wilson S, Bunce C, Mazzatti DJ. Pflugers Arch. 2010 Mar;459(4):619-30. PMID: 19898975 Lack of functional and expression homology between human and mouse aldo-keto reductase 1C enzymes: implications for modelling human cancers. Veli?a P, Davies NJ, Rocha PP, Schrewe H, Ride JP, Bunce CM. Mol Cancer. 2009 Dec 14;8:121. PMID: 20003443 Combined bezafibrate and medroxyprogesterone acetate: potential novel therapy for acute myeloid leukaemia. Khanim FL, Hayden RE, Birtwistle J, Lodi A, Tiziani S, Davies NJ, Ride JP, Viant MR, Gunther UL, Mountford JC, Schrewe H, Green RM, Murray JA, Drayson MT, Bunce CM. PLoS One. 2009 Dec 7;4(12):e8147. PMID: 19997560 Characterization of two novel aldo-keto reductases from Arabidopsis: expression patterns, broad substrate specificity, and an open active-site structure suggest a role in toxicant metabolism following stress. Simpson PJ, Tantitadapitak C, Reed AM, Mather OC, Bunce CM, White SA, Ride JP. J Mol Biol. 2009 Sep 18;392(2):465-80. PMID: 19616008 AKR1C isoforms represent a novel cellular target for jasmonates alongside their mitochondrial-mediated effects. Davies NJ, Hayden RE, Simpson PJ, Birtwistle J, Mayer K, Ride JP, Bunce CM. Cancer Res. 2009 Jun 1;69(11):4769-75. PMID: 19487289 Analysis of the role of COP9 Signalosome (CSN) subunits in K562; the first link between CSN and autophagy. Pearce C, Hayden RE, Bunce CM, Khanim FL. BMC Cell Biol. 2009 Apr 28;10:31. PMID: 19400951 The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: implications for leukemogenesis. Birtwistle J, Hayden RE, Khanim FL, Green RM, Pearce C, Davies NJ, Wake N, Schrewe H, Ride JP, Chipman JK, Bunce CM. Mutat Res. 2009 Mar 9;662(1-2):67-74. PMID: 19162045 Metabolomic profiling of drug responses in acute myeloid leukaemia cell lines. Tiziani S, Lodi A, Khanim FL, Viant MR, Bunce CM, Günther UL. PLoS One. 2009;4(1):e4251. Epub 2009 Jan 22. Erratum in: PLoS One. 2009;4(4). doi: 10.1371/annotation/39584d38-04f5-4b37-bfd8-eae2318ec6f9. PMID: 19158949 Elevated FOSB-expression; a potential marker of valproate sensitivity in AML. Khanim FL, Bradbury CA, Arrazi J, Hayden RE, Rye A, Basu S, MacWhannell A, Sawers A, Griffiths M, Cook M, Freeman S, Nightingale KP, Grimwade D, Falciani F, Turner BM, Bunce CM, Craddock C. Br J Haematol. 2009 Feb;144(3):332-41. PMID: 19036090 Treatment of primary CLL cells with bezafibrate and medroxyprogesterone acetate induces apoptosis and represses the pro-proliferative signal of CD40-ligand, in part through increased 15dDelta12,14,PGJ2. Hayden RE, Pratt G, Davies NJ, Khanim FL, Birtwistle J, Delgado J, Pearce C, Sant T, Drayson MT, Bunce CM. Leukemia. 2009 Feb;23(2):292-304. PMID: 18923439